Rivastigmine
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Rivastigmine: From Alzheimer's Disease to Glaucoma
One-Sentence Summary
Rivastigmine is a cholinesterase inhibitor originally used to treat Alzheimer's disease and related dementias. The TxGNN model predicts it may be effective for glaucoma, but the support is limited to 0 clinical trials and 3 publications (one animal study and two reviews).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Alzheimer's disease (the approved indication text is not available in the Singapore licence records; this is taken from the drug's known indication list) |
| Predicted New Indication | Glaucoma |
| TxGNN Prediction Score | 99.27% |
| Evidence Level | L3 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 7 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, rivastigmine inhibits both acetylcholinesterase and butyrylcholinesterase. This raises acetylcholine levels and strengthens cholinergic signalling, which is how it helps cognition in Alzheimer's disease and Parkinson's disease dementia.
Glaucoma is a different kind of disease, but cholinergic tone in the eye matters. Stronger cholinergic activity at the ciliary muscle and trabecular meshwork can increase aqueous humour outflow and lower intraocular pressure (IOP). Cholinergic agents such as pilocarpine already work this way. A 2000 rabbit study found that topical rivastigmine lowered IOP, and a 2024 review of cholinergic agents for IOP reduction supports the idea that this approach is plausible.
The evidence is preclinical only, and no human trials have been identified. Any move toward use in the eye would need an ocular safety assessment, covering miosis, effects on the ocular surface and cholinergic side effects.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 10673128 | 2000 | Preclinical animal study | J Ocul Pharmacol Ther | Topical rivastigmine lowered intraocular pressure in normotensive rabbits |
| 39130374 | 2024 | Review | Front Mol Biosci | Systems genetics and molecular review of cholinergic agents for IOP reduction; supports the plausibility of the cholinergic approach |
| 27967267 | 2017 | Review | Expert Opin Ther Pat | Patent review of AChE inhibitors and reactivators; notes that mild AChE inhibition has therapeutic relevance in Alzheimer's disease, myasthenia gravis and glaucoma |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN10035P | EXELON CAPSULE 1.5 mg | Capsule | Not stated in the records |
| SIN10036P | EXELON CAPSULE 3 mg | Capsule | Not stated in the records |
| SIN10037P | EXELON CAPSULE 4.5 mg | Capsule | Not stated in the records |
| SIN10038P | EXELON CAPSULE 6 mg | Capsule | Not stated in the records |
| SIN13450P | Exelon Patch 5 (4.6mg/24hr) | Patch, extended release | Not stated in the records |
Two further registrations are also valid: SIN13451P (Exelon Patch 10, 9.5 mg/24 hr) and SIN14500P (Exelon Patch 15, 13.3 mg/24 hr). All 7 registrations are valid single-ingredient products, with no cancelled licences. Only oral capsule and transdermal patch forms are registered, with no ophthalmic formulation.
Safety Considerations
- Conditions flagged as potential contraindications or cautions (from the knowledge graph, not label text): epilepsy, asthma and COPD, Parkinson disease and other parkinsonian disorders, basal ganglia disease, focal hand dystonia, blepharospasm, sick sinus syndrome, atrioventricular block and other heart conduction disease, sudden cardiac arrest, active peptic ulcer disease, diarrhoeal disease, anorexia nervosa and urinary tract obstruction.
- Drug Interactions: 100 interactions were found. One is rated Major: bupropion. Most of the others are Moderate, including anticholinergic agents (atropine, hyoscyamine, glycopyrronium, dicyclomine, trospium, clidinium, mepenzolate), acid suppressants (famotidine, ranitidine, cimetidine), loperamide, metronidazole, clarithromycin, levofloxacin, dolasetron, palonosetron and bowel-preparation products.
- Movement-related signals: The retrieved literature, including a 2025 systematic review and a case report of dyskinesia with the 13.3 mg/24 hr patch, shows that cholinesterase inhibitors can cause or worsen movement disorders.
Please refer to the package insert for full warnings and contraindications.
Other Predicted Indications (Context)
Of the other nine predictions, only extrapyramidal and movement disease has any literature. That literature is indirect and mainly records safety concerns. The rest (acute intermittent porphyria, psychogenic movement disorders, primary orthostatic tremor, tremor-nystagmus-duodenal ulcer syndrome, benign shuddering attacks, benign paroxysmal tonic upgaze of childhood with ataxia, chronic tic disorder and primary hereditary glaucoma) have no trials or literature and rest on computation alone. Primary hereditary glaucoma should be considered under the general glaucoma indication.
Conclusion and Next Steps
Decision: Hold
Rationale: Glaucoma is the best-supported prediction, but the evidence is one rabbit study and two reviews, with no human data. No ophthalmic formulation is registered in Singapore. Package insert safety data is also missing, and the knowledge graph flags several cardiac, respiratory, gastrointestinal and neurological cautions.
To proceed, the following is needed:
- The package insert warnings and contraindications from the HSA, so that safety screening can be completed
- Detailed mechanism of action data (from DrugBank)
- Confirmation of the approved indication text for the Singapore registrations
- Further preclinical work on IOP lowering (for example, other species and dose-response), followed by an ocular safety assessment for a topical formulation (miosis, ocular surface effects, systemic cholinergic effects)
- A plan for early-phase human studies, if the preclinical work is supportive
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.